Dabuzalgron

Drug Profile

Dabuzalgron

Alternative Names: R 450; RO 115-1240

Latest Information Update: 19 May 2004

Price : $50

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical
  • Class Antispasmodics; Imidazoles; Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Stress incontinence

Most Recent Events

  • 30 Apr 2004 Discontinued - Phase-II for Stress incontinence in Europe (PO)
  • 30 Apr 2004 Discontinued - Phase-I for Stress incontinence in Japan (PO)
  • 05 Feb 2004 A study has been added to the adverse events and Genitourinary Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top